Technology news and discussion on TalkFuse.
Demis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEO
Isomorphic Labs has raised $5 billion in a funding round to advance AI-designed medicines. The company, founded by Demis Hassabis, says the money will support its drug design work and move its first treatments towards clinical trials.
The Series C was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and Alphabet. Hassabis stepped back as Google DeepMind CEO three and a half months ago but remains Isomorphic’s CEO; the company spun out of DeepMind in 2021. Drug discovery startups have raised a record $23.2 billion in 2026, while Isomorphic’s previous round was $2.1 billion in May.
In short
- Isomorphic Labs raised $5 billion to develop medicines using AI.
- Hassabis remains CEO after stepping back from Google DeepMind.
- Drug discovery startups have raised a record $23.2 billion this year.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
The funding could give Isomorphic Labs the resources to turn promising AI-designed drug candidates into treatments that can be tested in clinical trials. Supporters may see the investment as a way to speed up drug discovery and attract capital to a field with significant potential health benefits.
The case against
A $5 billion investment in a company whose treatments have yet to reach clinical trials is a substantial bet on technology that has not yet demonstrated success in patients. Critics may question whether the funding and high-profile links to Google and major investors risk inflating expectations or concentrating influence before the approach is proven.
Explained simply
Isomorphic Labs is a drug discovery company founded by Demis Hassabis, who also founded Google DeepMind, the artificial intelligence research organisation. It spun out of DeepMind in 2021 and uses artificial intelligence to help design medicines.
Developing a new medicine can take years of research and testing before it is tried in people. Isomorphic says it aims to move its first treatments towards clinical trials, where medicines are tested for safety and effectiveness.
Hassabis remains Isomorphic’s chief executive after stepping back from leading Google DeepMind. The company’s work sits within a fast-growing field of startups seeking to use AI in drug discovery.
AI Business Companies Technology